This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a retrospective case-control study, which was carried out in a single centre. The patient were allocated to the study groups, based on recommendation by the attending physician and patient preferences after a discussion of the risks and benefits of each method. After transplantation, patients in both groups received similar infectious disease prophylaxis and immune-suppressive medication tapers. The median follow-up was 18 months. Loss to follow-up was observed only in the quality of life study, where only 25 (52%) TCD and 53 (54%) IST patients provided valid data.
Analysis of effectiveness
All of the patients whose records were reviewed were taken into account when estimating the effectiveness. However, in the quality of life study only those who completed the questionnaire were included in the analysis. The primary health outcomes were: the cumulative incidence of relapse at one year, the cumulative incidence of grades II to IV acute GVHD at 100 days, the cumulative incidence of extensive chronic GVHD at one year, event-free survival at one year, survival at one year, organ toxicity (pulmonary, veno-occlusive disease, renal/bladder, infectious), cause of death (relapse, GVHD, pulmonary, infection, other), and quality of life.
Clinical data were extracted from the clinical transplant database. Quality of life was estimated using the SF-36 questionnaire, the Quality of Life Index (QLI), and a rating scale (RS). The SF-36 questionnaire comprised 8 domains (physical functioning, role limitations, bodily pain, general health perceptions, vitality, social functioning, and emotional well-being) and 2 composite scales (physical and mental functioning). The authors compared survival, estimated using the Kaplan-Meier method, in a Cox regression analysis. This analysis was adjusted for patient age (50 years or less versus over 50 years), gender matching (female donor and male patients versus all other combinations), degree of human leukocyte antigen match (matched versus mismatched), patient cytomegalovirus serostatus (seronegative versus seropositive), and disease risk (low versus high). The study groups were comparable at baseline in terms of their demographics and several clinical conditions. However, there were more low-risk patients and less mismatched donor situations in the TDC group than in the IST group. Further, there were more patients with acute leukaemia in the TDC group, and more patients with chronic myelogenous leukaemia and myelodysplastic syndrome in the IST group.
Effectiveness results
The cumulative incidence of relapse at one year was 16% (+/-5) in the TCD group and 15% (+/-4) in the IST group.
The cumulative incidence of grades II to IV acute GVHD at 100 days was 46% (+/-7) in the TCD group and 36% (+/-5) in the IST group.
The cumulative incidence of extensive chronic GVHD at one year was 9% (+/-4) in the TCD group and 9% (+/-3) in the IST group.
Pulmonary toxicity occurred in 15% of the patients in the TCD group and 28% in the IST group.
Veno-occlusive disease occurred in 8% of the TCD group and 22% of the IST group.
Renal/bladder toxicity occurred in 8% of the TCD group and 10% of the IST group.
Infectious toxicity occurred in 8% of the TCD group and 11% of the IST group.
The death rate due to relapse was 16% in the TCD group and 31% in the IST group.
The death rate due to GVHD was 12% in the TCD group and 18% in the IST group.
The death rate due to pulmonary disease was 44% in the TCD group and 39% in the IST group.
The death rate due to infection was 32% in the TCD group and 23% in the IST group.
The death rate due to other causes was 24% in the TCD group and 24% in the IST group.
Only the difference in organ toxicity due to veno-occlusive disease reached statistical significance.
In terms of quality of life, the authors stated that there were no statistically significant differences among those who participated in the quality of life study and those who refused to participate.
There were generally no statistically significant differences between the two study groups in any of the quality indices and dimensions. The exception was the 'pain' dimension of the SF-36, which was significantly higher in the TCD group (100) than in the IST group (74), (p=0.03).
The Cox regression analysis showed that only the age of 50 years or less, and low-risk status predicted survival.
Clinical conclusions
The effectiveness analysis showed that the two prophylaxis methods led to similar clinical outcomes and survival.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used. Thus it would appear that a cost-consequences analysis was conducted. However, it is worth noting that although most of the outcome measures were not statistically different in the two study groups, the authors did not state that a cost-minimisation analysis was conducted.
Direct costs
Discounting was not applied since the costs were incurred over one year. The unit costs were not reported separately from the quantities of resources, and there was no breakdown of the cost items. The health service costs included in the economic evaluation were inpatient charges and total hospital days for the first year after transplantation. Professional charges and outpatient medical costs were not included in the analysis. The cost/resource boundary adopted in the study was not explicitly reported, but appears to have been that of the hospital. The costs and quantities were estimated using actual data derived from the hospital administrative database during January 1997 and December 1999. One patient was excluded from the analysis due to a research administrative error. All of the costs were inflated to year 2000 using the medical care component of the consumer price index.
